carmustine / Generic mfg. - LARVOL DELTA

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis (ASH 2025) - "First-line treatments were mainly HD-MTX alone (38%),HD-MTX + temozolomide (17%), or vincristine + procarbazine (12%)...Twelve patients (29%) underwent consolidative autologoustransplant, most commonly with thiotepa/carmustine (TT/BCNU, 69%) or BEAM conditioning (25%).Median duration of follow-up was 10.4 months... Forty-two pts met inclusion criteria. Median age was 57 (range 19–77), 69% were male, and 79%were white. Most (69%) had ECOG 0–1."

Retrospective data • CNS Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Solid Organ Transplantation • T Cell Non-Hodgkin Lymphoma • ALK • DNMT3A • TP53

Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients (ASH 2025) - "Thelymphodepletion regime of these patients was modified BEAC regime, include carmustine (125mg/m2 onDay −8 to Day −7), etoposide (125 mg/m2, Day −6 to Day −3), cytarabine (250 mg/m2, Day −6 to Day −3),and cyclophosphamide (45 mg/kg, Day −7 to Day −6). The modified BEACregimen enabled timely hematopoietic recovery. These findings support the feasibility of this approachand warrant further validation in larger cohorts."

Clinical • Diffuse Large B Cell Lymphoma • High-grade B-cell lymphoma • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Thrombocytopenia

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial (ASH 2025) - P2 | "Background : The incorporation of novel agents such as brentuximab vedotin (BV) and immunecheckpoint blockade (ICB) into salvage therapy for relapsed or refractory (rel/ref) classical Hodgkinlymphoma (cHL) has significantly improved long-term outcomes for patients...Those who achieved CR following two or four cycles of pembrolizumab-GVD proceeded to high-dose therapy with BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous hematopoieticstem cell transplantation (HDT/AHCT)...Thirteen patients (33%) received maintenance post-ASCT with BV (n=12) or BV-nivolumab (n=1, as part of a clinical trial), for a median of 5 cycles (range 1-11).Two patients (5%) received radiation therapy (RT) prior to HDT/ASCT... Pembrolizumab-GVD followed by consolidative HDT/AHCT achieves durable and long-termresponses in patients with rel/ref cHL, with a manageable safety profile. Based on the robust long-termoutcomes seen in this study, our group is evaluating whether HDT/AHCT..."

Clinical • P2 data • Autoimmune Hemolytic Anemia • Bone Marrow Transplantation • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma (ASH 2025) - "Although carmustine, etoposide, cytarabine, and melphalan (BEAM) is widely used for ASCTconditioning, the rising costs, limited availability, and pneumonitis risks of carmustine have reduced itsfeasibility in some settings...Here, we report our institutional experience with BuMelconditioning, incorporating pharmacokinetic (PK)-guided busulfan dosing to optimize dosing and mitigatetoxicity. This retrospective single-centre study included consecutive patients ≥18 years old who receivedrituximab (R)-BuMel conditioned ASCT for relapsed/refractory DLBCL between 2012 and 2024.Conditioning consisted of rituximab 375 mg/m2 IV on day -5, busulfan 3.2 mg/kg/day IV on days -4 to -2,and melphalan 140 mg/m2 IV on day -1... These results demonstrate the efficacy and tolerability of PK-guided BuMel conditioning forpatients undergoing ASCT for relapsed/refractory DLBCL, with PFS and OS comparable to thosehistorically reported with BEAM. Drug acquisition costs are considerably lower with..."

PK/PD data • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • High-grade B-cell lymphoma • Immunology • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Mucositis • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases • T Cell Histiocyte Rich Large B Cell Lymphoma • Transplantation • BCL2

Encapsulation-based enhancements in modern drug delivery systems. (PubMed, Int J Pharm) - "In addition, the pharmaceutical industry has commercialized many encapsulated drugs, such as anti-inflammatory (ibuprofen, dexamethasone), high blood pressure drugs (valsartan, azilsartan), proton pump inhibitors (lansoprazole), anti-cancer (carboplatin, carmustine, cisplatin, trastuzumab, cytarabine, paclitaxel, doxorubicin (DOX), vincristine) antiparasitic (amphotericin), antifungal (clotrimazole), and hormonal (melatonin (MLT))). It can render drugs more convenient and user-friendly for various therapeutic purposes and help to enhance their performance, functionality, and effectiveness. This comprehensive review examines the encapsulation technologies employed in the pharmaceutical industry, highlighting notable examples of encapsulated drugs that demonstrate their mechanism of action and potential therapeutic effects in vitro, in vivo, and through clinical trials, with relevance to various diseases."

Journal • Review • Cardiovascular • Hypertension • Oncology

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Oct 2027 ➔ Oct 2029 | Trial primary completion date: Oct 2027 ➔ Oct 2029

Trial completion date • Trial primary completion date • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation • CD34

Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma (PubMed, Zhonghua Nei Ke Za Zhi) - "Objective: To evaluate the efficacy and safety of the Chi-BEAM regimen (chidamide combined with carmustine, etoposide, cytarabine, and melphalan) followed by autologous hematopoietic stem cell transplantation (ASCT) in patients with high-risk or relapsed/refractory lymphoma. The regimen was well-tolerated; mild-to-moderate hypocalcemia within 1 week post-infusion and transient mild erythrocyturia on the infusion day were the primary adverse reactions. The Chi-BEAM regimen combined with ASCT demonstrates both safety and clinical benefit in patients with high-risk or relapsed/refractory lymphoma."

Journal • Retrospective data • Bone Marrow Transplantation • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Transplantation

Rituximab Ibrutinib Lenalidomide (R2I) Combination for Primary or Secondary Large B-Cell CNS Lymphoma: Last Resort or Bridge to Cellular Therapy? (ASH 2023) - "One PCNSL patient in CR received carmustine (BCNU) and thiotepa conditioning followed by autograft rescue and remains in remission 16 months post-ASCT. The second patient received CD19-targeted CAR T-cell therapy with axicabtagene ciloleucel for SCNSL... R2I is an effective and safe regimen in patients with PCNSL and SCNSL. Although responses without consolidation may be durable, R2I should be considered as an active drug combination and well-tolerated bridge to cellular therapy to achieve long term survival."

B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Glioblastoma Treatment in Latin America: A Scoping Review. (SNO 2025) - "Therapeutic approaches varied widely, with frequent use of surgery (including sodium fluorescein and awake craniotomy), 3D/IMRT radiotherapy (RT), and temozolomide in concurrent/adjuvant settings...Some studies reported carmustine, bevacizumab, or nimotuzumab...Intraoperative fluorescein and total resection were also associated with longer OS (15 vs 8 months, p=0.002; 30.7 vs 13.6 months, p=0.02). This review reveals heterogeneity in treatment, limited standardization, and a need for regionally adapted guidelines and access to innovative therapeutic options, resource-appropiate protocols and equitable care."

Review • Addiction (Opioid and Alcohol) • Brain Cancer • Glioblastoma • Solid Tumor

Recurrent Glioblastoma in Argentina: Bridging Global Standards with Local Realities (SNO 2025) - "Among Beva-based regimens (bevacizumab ± irinotecan) versus non-Beva therapies (carmustine, temozolomide rechallenge, reirradiation, reoperation), medians were 4.20 vs 6.24 months (log-rank p=0.032; not significant in Cox model, p=0.509). In conclusion, biomarkers and initial clinical response emerged as relevant prognostic factors. Although Beva-based therapies showed no clear benefit in PFS-2L, access to 2L treatment was associated with improved OS, highlighting the need to individualize therapeutic strategies in recurrent GBM."

Clinical • Brain Cancer • Glioblastoma • Solid Tumor • EGFR

Recurrent Glioblastoma in Argentina: Bridging Global Standards with Local Realities (SNO 2025) - "Among Beva-based regimens (bevacizumab ± irinotecan) versus non-Beva therapies (carmustine, temozolomide rechallenge, reirradiation, reoperation), medians were 4.20 vs 6.24 months (log-rank p=0.032; not significant in Cox model, p=0.509). In conclusion, biomarkers and initial clinical response emerged as relevant prognostic factors. Although Beva-based therapies showed no clear benefit in PFS-2L, access to 2L treatment was associated with improved OS, highlighting the need to individualize therapeutic strategies in recurrent GBM."

Clinical • Brain Cancer • Glioblastoma • Solid Tumor • EGFR

Efficacy and Safety of Chidamide Combined with BEAM Conditioning Regimen in Autologous Transplantation for T-Cell Lymphoma (ASH 2023) - "Aims: This prospective Phase II trial aims to evaluate the efficacy and safety of chidamide in combination with carmustine, etoposide, cytarabine, and melphalan (Chi-BEAM) conditioning regimen in ASCT of TCL patients received CR/PR to first-line chemotherapy. Chidamide combined with BEAM as a conditioning regimen for ASCT can significantly improve PFS and OS in TCL patients, and the AEs are controllable. The study is ongoing and further results will be continuously released."

Clinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK

Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov) - P1/2 | N=109 | Recruiting | Sponsor: Thomas Jefferson University | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2032 ➔ Aug 2032 | Trial primary completion date: May 2030 ➔ Oct 2030

Enrollment open • Trial completion date • Trial primary completion date • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Unveiling the culprits: A retrospective case-control study on risk factors of mucositis in autologous stem cell transplantation. (PubMed, Medicine (Baltimore)) - "Univariate analysis identified the BEAM conditioning regimen, comprising carmustine, etoposide, cytarabine, and melphalan (P = .03), along with post-transplant infections (P = .02), as significant risk factors for the onset of mucositis. Early identification of individuals at high risk, optimization of conditioning regimens, rigorous infection control protocols, and proactive oral care interventions may reduce the incidence and severity of mucositis, thereby improving patient outcomes. Further prospective studies are warranted to validate these findings and refine preventive strategies."

Journal • Retrospective data • Bone Marrow Transplantation • Hematological Disorders • Infectious Disease • Mucositis • Neutropenia • Stomatitis • Transplantation

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - P2 | N=59 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov) - P2 | N=16 | Recruiting | Sponsor: Leland Metheny | Suspended ➔ Recruiting

Enrollment open • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • IDH1

Recurrent Glioblastoma in Argentina: Bridging Global Standards with Local Realities (WFNOS 2025) - "Among Beva-based regimens (bevacizumab ± irinotecan) versus non-Beva therapies (carmustine, temozolomide rechallenge, reirradiation, reoperation), medians were 4.20 vs 6.24 months (log-rank p=0.032; not significant in Cox model, p=0.509). In conclusion, biomarkers and initial clinical response emerged as relevant prognostic factors. Although Beva-based therapies showed no clear benefit in PFS-2L, access to 2L treatment was associated with improved OS, highlighting the need to individualize therapeutic strategies in recurrent GBM."

Clinical • Brain Cancer • Glioblastoma • Solid Tumor • EGFR

Glioblastoma Treatment in Latin America: A Scoping Review. (WFNOS 2025) - P2 | "Therapeutic approaches varied widely, with frequent use of surgery (including sodium fluorescein and awake craniotomy), 3D/IMRT radiotherapy (RT), and temozolomide in concurrent/adjuvant settings...Some studies reported carmustine, bevacizumab, or nimotuzumab...Intraoperative fluorescein and total resection were also associated with longer OS (15 vs 8 months, p=0.002; 30.7 vs 13.6 months, p=0.02). This review reveals heterogeneity in treatment, limited standardization, and a need for regionally adapted guidelines and access to innovative therapeutic options, resource-appropiate protocols and equitable care."

Review • Addiction (Opioid and Alcohol) • Brain Cancer • Glioblastoma • Solid Tumor

Recurrent Glioblastoma in Argentina: Bridging Global Standards with Local Realities (WFNOS 2025) - P | "Among Beva-based regimens (bevacizumab ± irinotecan) versus non-Beva therapies (carmustine, temozolomide rechallenge, reirradiation, reoperation), medians were 4.20 vs 6.24 months (log-rank p=0.032; not significant in Cox model, p=0.509). In conclusion, biomarkers and initial clinical response emerged as relevant prognostic factors. Although Beva-based therapies showed no clear benefit in PFS-2L, access to 2L treatment was associated with improved OS, highlighting the need to individualize therapeutic strategies in recurrent GBM."

Clinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor • EGFR

An Open Label Study Comparing Photobiomodulation Therapy to Cryotherapy in Patients at High Risk for Drug-Induced Oral Mucositis (ASH 2023) - "Patients ≥ 18 years of age, receiving therapies with high potential to induce OM, including the conditioning regimen high-dose melphalan, carmustine/etoposide/cytarabine/melphalan (BEAM), thiotepa/etoposide/cytarabine/melphalan (TEAM), fludarabine/thiotepa/melphalan (FTM) and fludarabine/melphalan (FM) or chemotherapy protocols with high-dose MTX, are included in this trial...Our objective is to provide data that may guide the development of a standardized OM prophylaxis for patients undergoing high-dose chemotherapy. At the time of abstract submission, 8 patients have been randomized in the study."

Clinical • Hematological Malignancies • Infectious Disease • Mucositis • Oncology • Stomatitis

Long Term Disease Free Survival and Survival of Patients with Relapsed Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplantation (ASH 2023) - "The preparative regimen was carmustine, etoposide, and melphalan (CEM,1992-2005) and BCNU, etoposide, cytarabine, and melphalan (BEAM, 2006 to present). Brentuximab was added was added to BEAM in 2018 as post-transplant consolidation therapy in 13 patients. All patients underwent mobilized peripheral blood stem cell collections with high dose filgrastim and since 2008 filgrastim and plexiform...Patients with relapsed HL can achieve long term curative outcomes when treated with ABMT. The most frequent long term complication is cardiomyopathy."

Clinical • Breast Cancer • Cardiomyopathy • Cardiovascular • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Liposarcoma • Lymphoma • Oncology • Sarcoma • Septic Shock • Solid Tumor • Transplantation • CD34

The Role of High-Dose Regimens Followed By Autologous Stem Cell Transplantation for Salvage Chemotherapy-Sensitive DLBCL Patients (ASH 2023) - "Introduction: It has been reported that lisocabtagene maraleucel improved event-free survival and complete response rate compared with standard care as second -line therapy for early relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) patients(pts)...Further, we have also used ranimustine (MCNU) based MEAM regimen due to not availability for carmustine in Japan...AECC regimen consists of nimustine 200mg/m 2 on day -7 to day -6, etoposide (ETP) 30mg/kg on day -5 to day -4, cyclophosphamide 60mg/kg on day -3 to day -2, carboplatin 700mg/m 2 on day -3 to day -2. MEAM regimen consists of MCNU 300 mg/m 2 on day -7, ETP 200 mg/m 2 on day -6 to day -3, cytarabine 200 mg/m 2 q12 hrs on day -6 to day -3, and melphalan 140 mg/m 2 on day -2...However, AECC was associated with a higher incidence of cardiac toxicity and TRM within 100 days. It was suggested that auto-SCT with AECC may be a treatment option when CAR T-cell therapy was not available."

Clinical • B Cell Lymphoma • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Transplantation

Mitoxantrone Hydrochloride Liposome Injection Combined with Carmustine, Etoposide, and Cytarabine As Conditioning of Autologous Hematopoietic Stem Cell Transplantation in NHL Patients: a Prospective Single-Arm Clinical Trial (ASH 2023) - P=N/A | "Mitoxantrone hydrochloride liposome injection combined with carmustine, etoposide, cytarabine (modified BEAM protocol) was a well-tolerated and effective conditioning regimen for NHL and the study is ongoing and updated results will be presented in the future."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Constipation • Cough • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypotension • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Mediastinal B Cell Lymphoma • Mucositis • Natural Killer/T-cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases • Septic Shock • Sezary Syndrome • Stomatitis • T Cell Non-Hodgkin Lymphoma • Transplantation

The Treatment of Burkitt Lymphoma with the Berlin-Frankfurt-Münster Protocol with Rituximab and Autologous Transplantation (ASH 2023) - "Treatment plan consisted of 3 blocks, A (ifosfamide, vincristine, methotrexate, etoposide, cytarabine), B (vincristine, cyclophosphamide, methotrexate, doxorubicin) and C (vindesine, methotrexate, etoposide, cytarabine), each repeated twice, every 28 days...Autologous stem cells were reinfused (ASCT) at the end of the 6-blocks after BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning, when feasible...Infections occurred in 60% of patients; grade 4 and fatal sepsis in 14% and 8% of cases. Intensive treatment according to BFM protocol, with rituximab and ASCT, appears feasible, safe and highly effective in adult patients with BL, as confirmed by long-term survival rates."

Clinical • Anemia • Burkitt Lymphoma • Cardiovascular • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Mucositis • Neutropenia • Oncology • Septic Shock • Thrombocytopenia • Transplantation

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 'Wamm' Trial (ASH 2023) - P2 | "RDHAOx chemotherapy (rituximab, dexamethasone, cytarabine, oxaliplatin) prior to ASCT provides a complete response (CR) rate of 77% and favourable toxicity compared to many induction regimens (Le Gouill Blood 2017). Furthermore, Obinutuzumab-DHAP yields undetectable minimum residual disease (MRD) in 85% of young MCL patients...Those with an objective response (CR or partial response-PR) underwent BEAM ASCT (carmustine, etoposide, cytarabine, melphalan) then AR maintenance (A; 1yr continuous & R; 3-monthly x 8 cycles)...An AR window yields a high ORR and compared to historical studies, improves post-chemo induction CR rates and MRD negativity. A telehealth model allowed rapid recruitment in a rare cancer."

Clinical • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Oncology • Pneumonia • Thrombocytopenia • TP53